Immuneering Corporation (IMRX)

NASDAQ: IMRX · IEX Real-Time Price · USD
10.13
-0.24 (-2.31%)
At close: Mar 27, 2023, 4:00 PM
10.33
+0.20 (1.97%)
After-hours: Mar 27, 2023, 6:51 PM EDT

Income Statement (Annual)

Millions USD. Fiscal year is Jan - Dec.
Year 2022202120202019
Revenue
0.322.082.311.92
Revenue Growth (YoY)
-84.76%-10.02%20.41%-
Cost of Revenue
0.161.151.281.22
Gross Profit
0.160.931.030.7
Selling, General & Admin
15.618.273.112.71
Research & Development
36.2726.54154.28
Other Operating Expenses
0.03000
Operating Expenses
51.934.8118.116.99
Operating Income
-51.74-33.89-17.08-6.29
Interest Expense / Income
0000.35
Other Expense / Income
-1.23-0.04-0.041.07
Pretax Income
-50.51-33.84-17.04-7.71
Income Tax
0-0.3100
Net Income
-50.51-33.54-17.04-7.71
Shares Outstanding (Basic)
261454
Shares Outstanding (Diluted)
261454
Shares Change
93.84%175.00%40.00%-
EPS (Basic)
-1.91-2.46-3.44-2.18
EPS (Diluted)
-1.91-2.46-3.44-2.18
Free Cash Flow Per Share
-1.70-2.27-2.96-1.26
Gross Margin
50.11%44.56%44.61%36.29%
Operating Margin
-16325.77%-1629.17%-739.01%-327.71%
Profit Margin
-15937.29%-1612.33%-737.17%-401.59%
Free Cash Flow Margin
-14148.44%-1486.17%-634.83%-232.48%
EBITDA
-49.72-33.68-16.96-7.34
EBITDA Margin
-15685.90%-1619.46%-733.74%-382.35%
Depreciation & Amortization
0.80.160.080.02
EBIT
-50.51-33.84-17.04-7.36
EBIT Margin
-15937.29%-1627.11%-737.17%-383.29%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).